ZA201407369B - Self-stabilizing linker conjugates - Google Patents

Self-stabilizing linker conjugates

Info

Publication number
ZA201407369B
ZA201407369B ZA2014/07369A ZA201407369A ZA201407369B ZA 201407369 B ZA201407369 B ZA 201407369B ZA 2014/07369 A ZA2014/07369 A ZA 2014/07369A ZA 201407369 A ZA201407369 A ZA 201407369A ZA 201407369 B ZA201407369 B ZA 201407369B
Authority
ZA
South Africa
Prior art keywords
self
linker conjugates
stabilizing linker
stabilizing
conjugates
Prior art date
Application number
ZA2014/07369A
Other languages
English (en)
Inventor
Doronina Svetlana
Lyon Robert
Bovee Timothy
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/799,244 external-priority patent/US9504756B2/en
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of ZA201407369B publication Critical patent/ZA201407369B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Insulating Materials (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2014/07369A 2012-05-15 2014-10-10 Self-stabilizing linker conjugates ZA201407369B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261647373P 2012-05-15 2012-05-15
US201361770983P 2013-02-28 2013-02-28
US201361773067P 2013-03-05 2013-03-05
US13/799,244 US9504756B2 (en) 2012-05-15 2013-03-13 Self-stabilizing linker conjugates
PCT/US2013/040951 WO2013173337A2 (en) 2012-05-15 2013-05-14 Self-stabilizing linker conjugates

Publications (1)

Publication Number Publication Date
ZA201407369B true ZA201407369B (en) 2020-02-26

Family

ID=49584442

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/07369A ZA201407369B (en) 2012-05-15 2014-10-10 Self-stabilizing linker conjugates

Country Status (15)

Country Link
EP (1) EP2850094B1 (enExample)
JP (5) JP6423340B2 (enExample)
KR (5) KR102144069B1 (enExample)
CN (2) CN104822656B (enExample)
AU (5) AU2013263002C1 (enExample)
BR (1) BR112014028222A2 (enExample)
CA (2) CA3131619A1 (enExample)
EA (1) EA037203B1 (enExample)
ES (1) ES2983109T3 (enExample)
HK (1) HK1207388A1 (enExample)
MX (2) MX368678B (enExample)
NZ (3) NZ741211A (enExample)
SG (2) SG10201608904YA (enExample)
WO (1) WO2013173337A2 (enExample)
ZA (1) ZA201407369B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013014583A (es) 2011-06-10 2014-03-31 Mersana Therapeutics Inc Conjugados de proteina-polimero-farmaco.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
JP6423340B2 (ja) * 2012-05-15 2018-11-14 シアトル ジェネティクス，インコーポレイティド 自己安定化リンカー結合体
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
DK3054992T3 (da) 2013-10-11 2019-10-28 Asana Biosciences Llc Protein-polymer-lægemiddelkonjugater
CA3187392A1 (en) 2013-10-15 2015-04-23 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
MX385651B (es) 2013-12-19 2025-03-18 Seagen Inc Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
FI3900742T3 (fi) * 2014-09-11 2024-08-16 Seagen Inc Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen
CA2962783A1 (en) * 2014-10-01 2016-04-07 Medimmune, Llc Method of conjugating a polypeptide
JP6723509B2 (ja) 2014-10-24 2020-07-15 日油株式会社 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
CN107206101B (zh) * 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
MX2017007629A (es) * 2014-12-09 2018-05-17 Abbvie Inc Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen.
EP3230283A1 (en) * 2014-12-09 2017-10-18 AbbVie Inc. Bcl-xl inhibitory compounds and antibody drug conjugates including the same
AU2016232839B2 (en) 2015-03-18 2021-02-25 Seagen Inc. CD48 antibodies and conjugates thereof
CN106267225B (zh) 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
CN106380508A (zh) * 2015-07-28 2017-02-08 上海皓元生物医药科技有限公司 一种抗体偶联药物连接子的工业化生产方法
CA2949032A1 (en) 2015-11-30 2017-05-30 Pfizer Inc. Site specific her2 antibody drug conjugates
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
SG10202010590UA (en) 2015-12-04 2020-12-30 Seattle Genetics Inc Conjugates of quaternized tubulysin compounds
US11844839B2 (en) 2016-03-25 2023-12-19 Seagen Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
CN109219610A (zh) * 2016-04-04 2019-01-15 新泽西州立拉特格斯大学 拓扑异构酶毒物
JP2019518013A (ja) * 2016-05-10 2019-06-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 安定性が向上したツブリシン類似体の抗体薬物結合体
WO2017214458A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
US20200121803A1 (en) 2016-06-08 2020-04-23 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CA3027178A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
BR112018075630A2 (pt) 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-cd98 e conjugados de fármaco de anticorpo
EP3468615A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-egfr antibody drug conjugates
UY37278A (es) 2016-06-08 2018-01-31 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
AU2017277534A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-EGFR antibody drug conjugates
JP2019521973A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｂｈ７−ｈ３抗体及び抗体薬物コンジュゲート
TWI851531B (zh) * 2016-08-09 2024-08-11 美商思進公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
KR20250044934A (ko) 2016-10-19 2025-04-01 인벤라 인코포레이티드 항체 구조물
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
MX2019007019A (es) 2016-12-22 2019-08-16 Univ Degli Studi Magna Graecia Catanzaro Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
CN107652219B (zh) * 2017-08-14 2021-06-08 上海新理念生物医药科技有限公司 四马来酰亚胺型连接子及其应用
KR20200051733A (ko) 2017-09-08 2020-05-13 시애틀 지네틱스, 인크. 튜불리신 및 그 중간물의 제조 공정
US11707531B2 (en) * 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
UA130009C2 (uk) 2018-05-07 2025-10-15 Генмаб А/С Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
CN120795120A (zh) 2018-06-05 2025-10-17 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US20220040320A1 (en) * 2018-12-21 2022-02-10 Seagen Inc. Adcs with thiol multiplex linkers
KR20220025861A (ko) * 2019-06-28 2022-03-03 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 항체 약물 복합체, 이의 중간체, 제조 방법 및 용도
KR20220079606A (ko) 2019-10-04 2022-06-13 씨젠 인크. 캄프토테신 펩티드 접합체
US20230173093A1 (en) * 2020-04-10 2023-06-08 Seagen Inc. Charge variant linkers
JP2023524812A (ja) * 2020-05-08 2023-06-13 エムペグ エルエイ リミテッド ライアビリティ カンパニー リンカー化合物
CN114306633A (zh) * 2020-09-29 2022-04-12 迈威(上海)生物科技股份有限公司 一种双取代桥连抗体偶联药物的制备方法
AU2020479745A1 (en) 2020-12-04 2023-07-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
TW202300178A (zh) 2021-03-18 2023-01-01 美商西根公司 內化的生物活性化合物偶聯物選擇性釋放藥物
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
KR20240051956A (ko) 2021-09-03 2024-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
PE20242179A1 (es) 2022-03-17 2024-11-07 Seagen Inc Conjugados de camptotecina
WO2024005123A1 (ja) 2022-06-30 2024-01-04 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
AU2023366495A1 (en) * 2022-10-28 2025-06-12 Eli Lilly And Company Self-hydrolyzing maleimides for bioconjugation
CN120417937A (zh) 2022-11-17 2025-08-01 赛诺菲 Ceacam5抗体-药物缀合物及其使用方法
EP4634227A1 (en) 2022-12-13 2025-10-22 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
AR131815A1 (es) * 2023-02-09 2025-05-07 Beigene Ltd Conjugados de enlace autoestabilizantes
TW202506691A (zh) 2023-04-20 2025-02-16 美商思進公司 Ｓｔｉｎｇ促效劑化合物及其結合物
WO2024258743A1 (en) 2023-06-13 2024-12-19 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
TW202500198A (zh) * 2023-06-29 2025-01-01 瑞士商百濟神州瑞士有限責任公司 生物活性偶聯物、其製備方法及用途
WO2025054181A1 (en) 2023-09-05 2025-03-13 Seagen Inc. Targeted degrader molecules and ligand drug conjugates thereof
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5523360A (en) * 1992-07-01 1996-06-04 Akzo Nobel N. V. Process for the modification of polyphenylene ether resin compositions in the presence of a citraconimide compound
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US5973166A (en) 1998-03-02 1999-10-26 The Dexter Corporation Method for the preparation of maleimides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US7432331B2 (en) * 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
DK1725249T3 (en) * 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
CN114053429A (zh) 2004-06-01 2022-02-18 健泰科生物技术公司 抗体-药物偶联物和方法
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
WO2007038658A2 (en) 2005-09-26 2007-04-05 Medarex, Inc. Antibody-drug conjugates and methods of use
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
PL2265283T3 (pl) 2008-03-18 2015-03-31 Seattle Genetics Inc Koniugaty aurystatyny lek łącznik
KR20210005318A (ko) 2008-04-30 2021-01-13 이뮤노젠 아이엔씨 가교제 및 그 용도
JP2012510798A (ja) * 2008-12-05 2012-05-17 アンジオケム インコーポレーテッド ペプチド治療剤コンジュゲートおよびその使用
JP5977522B2 (ja) 2009-02-05 2016-08-24 イミュノジェン・インコーポレーテッド 新規ベンゾジアゼピン誘導体
CA2948693C (en) * 2009-02-13 2018-09-04 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
RS52983B (sr) 2010-04-15 2014-02-28 Spirogen Sárl Pirolobenzodiazepini i njihovi konjugati
CA2815363C (en) * 2010-10-22 2020-07-14 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
TWI617555B (zh) 2011-02-15 2018-03-11 免疫原公司 細胞毒性苯并二氮呯衍生物
JP6423340B2 (ja) * 2012-05-15 2018-11-14 シアトル ジェネティクス，インコーポレイティド 自己安定化リンカー結合体
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof

Also Published As

Publication number Publication date
MX384366B (es) 2025-03-14
KR102144069B1 (ko) 2020-08-13
EP2850094A4 (en) 2016-07-06
JP7014856B2 (ja) 2022-02-01
CA2869777A1 (en) 2013-11-21
JP6709247B2 (ja) 2020-06-10
KR102433686B1 (ko) 2022-08-19
AU2020202805B2 (en) 2020-12-17
EP2850094B1 (en) 2024-04-17
JP2022044690A (ja) 2022-03-17
AU2021201636B2 (en) 2023-02-16
JP6423340B2 (ja) 2018-11-14
SG10201608904YA (en) 2016-12-29
AU2018201190A1 (en) 2018-03-08
CN104822656A (zh) 2015-08-05
MX2019012201A (es) 2019-11-28
CN108465112A (zh) 2018-08-31
MX2014013807A (es) 2015-02-04
MX368678B (es) 2019-10-11
AU2023203005A1 (en) 2023-06-01
NZ741211A (en) 2019-09-27
KR102475777B1 (ko) 2022-12-09
AU2013263002C1 (en) 2018-05-31
AU2013263002B2 (en) 2017-11-30
AU2021201636A1 (en) 2021-04-08
NZ630870A (en) 2016-10-28
WO2013173337A2 (en) 2013-11-21
EA037203B1 (ru) 2021-02-18
JP2024032941A (ja) 2024-03-12
JP2015521187A (ja) 2015-07-27
KR20210094150A (ko) 2021-07-28
JP2018162251A (ja) 2018-10-18
HK1207388A1 (en) 2016-01-29
JP7431261B2 (ja) 2024-02-14
KR20230113821A (ko) 2023-08-01
JP2020122023A (ja) 2020-08-13
CN104822656B (zh) 2018-05-01
KR102557309B1 (ko) 2023-07-20
AU2018201190B2 (en) 2020-01-30
BR112014028222A2 (pt) 2017-06-27
NZ724892A (en) 2018-04-27
EP2850094A2 (en) 2015-03-25
CA3131619A1 (en) 2013-11-21
CN108465112B (zh) 2022-04-29
KR20220166877A (ko) 2022-12-19
AU2013263002A1 (en) 2014-09-25
AU2020202805A1 (en) 2020-05-21
SG11201406252WA (en) 2014-10-30
CA2869777C (en) 2021-11-16
EA201401254A1 (ru) 2015-09-30
ES2983109T3 (es) 2024-10-21
KR20150009991A (ko) 2015-01-27
WO2013173337A3 (en) 2015-06-11
KR20200097000A (ko) 2020-08-14

Similar Documents

Publication Publication Date Title
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
ZA201407369B (en) Self-stabilizing linker conjugates
IL268420A (en) Oligonucleotide conjugates
ZA201900820B (en) Antibody-drug conjugate
IL263973B (en) Protein-polymer-drug conjugates
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
ZA201501996B (en) Drug-protein conjugates
IL237672A0 (en) Drug-protein conjugates
IL228404A0 (en) Antibody-drug captures
PL2717917T3 (pl) Koniugaty p97 - przeciwciało
ZA201409119B (en) Polymer-nsaid conjugate
IL233701B (en) Conjugates of a binding molecule